VEGF	O
,	O
angiopoietin	O
-	O
1	O
and	O
-	O
2	O
in	O
bronchial	O
asthma	O
:	O
new	O
molecular	O
targets	O
in	O
airway	B-Multi-tissue_structure
angiogenesis	O
and	O
microvascular	B-Tissue
remodeling	O
.	O

Airway	B-Multi-tissue_structure
angiogenesis	O
and	O
microvascular	B-Tissue
remodeling	O
are	O
known	O
features	O
of	O
bronchial	O
asthma	O
,	O
but	O
the	O
mechanisms	O
of	O
these	O
structural	O
alterations	O
are	O
just	O
beginning	O
to	O
be	O
elucidated	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
,	O
one	O
of	O
the	O
most	O
potent	O
angiogenic	O
factors	O
,	O
stimulates	O
endothelial	B-Cell
cell	I-Cell
proliferation	O
and	O
induces	O
the	O
angiogenesis	O
.	O

Recently	O
,	O
considerable	O
attentions	O
have	O
been	O
devoted	O
to	O
the	O
physiological	O
roles	O
of	O
angiopoietin	O
(	O
Ang	O
)	O
-	O
1	O
and	O
-	O
2	O
as	O
regulatory	O
factors	O
of	O
VEGF	O
.	O

Ang	O
-	O
1	O
has	O
been	O
shown	O
to	O
induce	O
the	O
migration	O
and	O
sprouting	O
of	O
endothelial	B-Cell
cells	I-Cell
,	O
and	O
coexpression	O
of	O
Ang	O
-	O
1	O
and	O
VEGF	O
enhanced	O
angiogenesis	O
.	O

In	O
the	O
presence	O
of	O
high	O
levels	O
of	O
VEGF	O
,	O
Ang	O
-	O
2	O
also	O
promotes	O
rapid	O
increase	O
in	O
capillary	B-Tissue
diameter	O
,	O
remodeling	O
of	O
the	O
basal	B-Cellular_component
lamina	I-Cellular_component
,	O
proliferation	O
and	O
migration	O
of	O
endothelial	B-Cell
cells	I-Cell
,	O
and	O
stimulates	O
sprouting	O
of	O
new	O
blood	B-Multi-tissue_structure
vessels	I-Multi-tissue_structure
.	O

Thus	O
,	O
VEGF	O
,	O
Ang	O
-	O
1	O
and	O
-	O
2	O
may	O
play	O
complementary	O
and	O
coordinated	O
roles	O
in	O
airway	B-Multi-tissue_structure
angiogenesis	O
and	O
microvascular	B-Tissue
remodeling	O
,	O
and	O
these	O
structural	O
changes	O
are	O
potentially	O
reversible	O
by	O
therapeutic	O
intervention	O
.	O

The	O
scope	O
of	O
the	O
present	O
review	O
is	O
to	O
discuss	O
from	O
a	O
clinical	O
point	O
of	O
view	O
the	O
potential	O
interactions	O
between	O
VEGF	O
and	O
angiopoietins	O
in	O
the	O
asthmatic	O
airways	B-Multi-tissue_structure
,	O
and	O
focus	O
on	O
the	O
therapeutic	O
implications	O
targeting	O
for	O
these	O
angiogenic	O
factors	O
.	O

Recently	O
,	O
there	O
is	O
an	O
increasing	O
number	O
of	O
patents	O
which	O
have	O
been	O
focused	O
on	O
the	O
inhibitors	O
of	O
VEGF	O
action	O
.	O

These	O
inhibitors	O
are	O
directed	O
towards	O
the	O
receptors	O
of	O
VEGF	O
or	O
intracellular	B-Immaterial_anatomical_entity
substrates	O
for	O
the	O
receptors	O
.	O

We	O
will	O
also	O
discuss	O
several	O
patents	O
regarding	O
inhibitors	O
of	O
VEGF	O
action	O
in	O
the	O
present	O
review	O
.	O

